

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 4.1      Revision Date: 15.10.2025      SDS Number: 7725086-00020      Date of last issue: 14.04.2025  
Date of first issue: 06.01.2021

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Kilsheelan  
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 1B      H360D: May damage the unborn child.  
Specific target organ toxicity - repeated exposure, Category 1      H372: Causes damage to organs through prolonged or repeated exposure.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :

Signal word : Danger

Hazard statements : H360D May damage the unborn child.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 4.1      Revision Date: 15.10.2025      SDS Number: 7725086-00020      Date of last issue: 14.04.2025  
Date of first issue: 06.01.2021

H372 Causes damage to organs through prolonged or repeated exposure.

Precautionary statements :

### Prevention:

P201 Obtain special instructions before use.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

### Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

### Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Pembrolizumab

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Pembrolizumab	1374853-91-4	Repr. 1B; H360D STOT RE 1; H372 (Immune system)	>= 10 - < 20
Berahyaluronidase alfa	2636716-20-4	Resp. Sens. 1; H334	< 0,1

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- |                            |   |   |
|----------------------------|---|---|
| General advice             | : | In the case of accident or if you feel unwell, seek medical advice immediately.<br>When symptoms persist or in all cases of doubt seek medical advice.  |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).   |
| If inhaled                 | : | If inhaled, remove to fresh air.<br>Get medical attention.  |
| In case of skin contact    | : | In case of contact, immediately flush skin with soap and plenty of water.<br>Remove contaminated clothing and shoes.<br>Get medical attention.<br>Wash clothing before reuse.<br>Thoroughly clean shoes before reuse. |
| In case of eye contact     | : | Flush eyes with water as a precaution.<br>Get medical attention if irritation develops and persists.  |
| If swallowed               | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention.<br>Rinse mouth thoroughly with water.   |

#### 4.2 Most important symptoms and effects, both acute and delayed

- |       |   |   |
|-------|---|---|
| Risks | : | May damage the unborn child.<br>Causes damage to organs through prolonged or repeated exposure. |
|-------|---|---|

#### 4.3 Indication of any immediate medical attention and special treatment needed

- |           |   |   |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

- |                              |   |  |
|------------------------------|---|--|
| Suitable extinguishing media | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical |
|------------------------------|---|--|

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

---

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

---

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

mine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

- |                         |   |  |
|-------------------------|---|--|
| Technical measures      | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.  |
| Local/Total ventilation | : | If sufficient ventilation is unavailable, use with local exhaust ventilation.  |
| Advice on safe handling | : | Do not get on skin or clothing.<br>Do not breathe mist or vapours.<br>Do not swallow.<br>Avoid contact with eyes.<br>Wash skin thoroughly after handling.<br>Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment<br>Keep container tightly closed.<br>Do not eat, drink or smoke when using this product.<br>Take care to prevent spills, waste and minimize release to the environment.                              |
| Hygiene measures        | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.<br>The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

### 7.2 Conditions for safe storage, including any incompatibilities

- |   |   |  |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.                      |
| Advice on common storage                      | : | Do not store with the following product types:<br>Strong oxidizing agents<br>Self-reactive substances and mixtures<br>Organic peroxides<br>Explosives<br>Gases |

### 7.3 Specific end use(s)

- |                 |   |                   |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 4.1      Revision Date: 15.10.2025      SDS Number: 7725086-00020      Date of last issue: 14.04.2025  
Date of first issue: 06.01.2021

### SECTION 8: Exposure controls/personal protection

#### 8.1 Control parameters

##### Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Pembrolizumab	1374853-91-4	TWA	450 µg/m <sup>3</sup> (OEB 2)	Internal
Berahyaluronidase alfa	2636716-20-4	TLV-C	0.06 ug/m <sup>3</sup> (OEB 5)	Internal
Further information: RSEN				
		Wipe limit	0.07 ug/100 cm <sup>2</sup>	

#### 8.2 Exposure controls

##### Engineering measures

The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

##### Personal protective equipment

- Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
Equipment should conform to NS EN 143

Filter type : Particulates type (P)

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Physical state : liquid

Form : liquid

Colour : No data available

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : 5,5  
No data available

Viscosity  
Viscosity, kinematic : No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

---

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : No data available

Relative density : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics  
Particle size : Not applicable

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

### SECTION 11: Toxicological information

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

##### Acute toxicity

Not classified based on available information.

##### Components:

##### Berahyaluronidase alfa:

Acute oral toxicity : Remarks: Not classified due to lack of data.  
Acute inhalation toxicity : Remarks: Not classified due to lack of data.  
Acute dermal toxicity : Remarks: Not classified due to lack of data.

##### Skin corrosion/irritation

Not classified based on available information.

##### Components:

##### Berahyaluronidase alfa:

Remarks : Not classified due to lack of data.

##### Serious eye damage/eye irritation

Not classified based on available information.

##### Components:

##### Berahyaluronidase alfa:

Remarks : Not classified due to lack of data.

##### Respiratory or skin sensitisation

##### Skin sensitisation

Not classified based on available information.

##### Respiratory sensitisation

Not classified based on available information.

##### Components:

##### Berahyaluronidase alfa:

Result : Sensitiser

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

---

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

#### **Berahyaluronidase alfa:**

Genotoxicity in vitro : Remarks: Not classified due to lack of data.

Genotoxicity in vivo : Remarks: Not classified due to lack of data.

Germ cell mutagenicity- Assessment : May cause genetic defects.

### Carcinogenicity

Not classified based on available information.

#### Components:

#### **Berahyaluronidase alfa:**

Remarks : Not classified due to lack of data.

### Reproductive toxicity

May damage the unborn child.

#### Components:

#### **Pembrolizumab:**

Reproductive toxicity - Assessment : May damage the unborn child., Based on data from similar materials

#### **Berahyaluronidase alfa:**

Effects on fertility : Remarks: Not classified due to lack of data.  
May cause adverse reproductive effects.

Effects on foetal development : Remarks: Not classified due to lack of data.  
May cause birth defects.

Reproductive toxicity - Assessment : May damage fertility. May damage the unborn child.

### STOT - single exposure

Not classified based on available information.

#### Components:

#### **Berahyaluronidase alfa:**

Assessment : May cause damage to organs.

Remarks : Not classified due to lack of data.

### STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version 4.1      Revision Date: 15.10.2025      SDS Number: 7725086-00020      Date of last issue: 14.04.2025  
Date of first issue: 06.01.2021

### Components:

#### **Pembrolizumab:**

Target Organs : Immune system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

#### **Berahyaluronidase alfa:**

Assessment : May cause damage to organs through prolonged or repeated exposure.  
Remarks : Not classified due to lack of data.

### **Repeated dose toxicity**

### Components:

#### **Pembrolizumab:**

Species : Monkey  
NOAEL : 200 mg/kg  
Application Route : Intravenous  
Exposure time : 180 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 200 mg/kg  
Application Route : Intravenous  
Exposure time : 180 d  
Remarks : No significant adverse effects were reported

#### **Berahyaluronidase alfa:**

Remarks : Not classified due to lack of data.  
May cause damage to organs.

### **Aspiration toxicity**

Not classified based on available information.

### Components:

#### **Berahyaluronidase alfa:**

Not applicable

## 11.2 Information on other hazards

### **Endocrine disrupting properties**

Not classified based on available information.

### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

#### Components:

##### **Pembrolizumab:**

Inhalation : Target Organs: Immune system  
Symptoms: Cough, Fatigue, Nausea, pruritis, Rash, constipation, joint pain, Diarrhoea, Pneumonia, decrease in appetite, Fever, anemia, neutropenia, musculoskeletal pain, Vomiting, confusion, Headache, Shortness of breath, Hypofunction of thyroid gland, May cause respiratory arrest., May cause, immune-mediated pneumonitis, colitis, hepatitis, nephritis  
Remarks: Damage to fetus possible

##### **Berahyaluronidase alfa:**

General Information : Avoid repeated exposure.  
May cause eye, skin, and respiratory tract irritation.  
May be harmful if swallowed.  
May be harmful if inhaled.  
May produce an allergic reaction.  
May cause heritable genetic damage.  
May cause adverse reproductive effects.  
May cause birth defects.  
May cause damage to organs.

### Further information

#### Components:

##### **Berahyaluronidase alfa:**

Remarks : The toxicological properties of this material have not been fully investigated

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### **Berahyaluronidase alfa:**

Toxicity to fish : Remarks: No data available  
Toxicity to daphnia and other aquatic invertebrates : Remarks: No data available  
Toxicity to algae/aquatic plants : Remarks: No data available  
Toxicity to daphnia and other : Remarks: No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

---

aquatic invertebrates (Chronic toxicity)

### Ecotoxicology Assessment

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

### 12.2 Persistence and degradability

#### Components:

#### **Berahyaluronidase alfa:**

Biodegradability : Remarks: No data available

Stability in water : Remarks: No data available

### 12.3 Bioaccumulative potential

No data available

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.  
According to the European Waste Catalogue, Waste Codes

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

are not product specific, but application specific.  
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.  
Do not dispose of waste into sewer.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

### SECTION 14: Transport information

#### 14.1 UN number or ID number

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

#### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA : Not regulated as a dangerous good

#### 14.4 Packing group

ADN : Not regulated as a dangerous good  
ADR : Not regulated as a dangerous good  
RID : Not regulated as a dangerous good  
IMDG : Not regulated as a dangerous good  
IATA (Cargo) : Not regulated as a dangerous good  
IATA (Passenger) : Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:  
Number on list 3

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EU) No 2024/590 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.  
Not applicable

#### Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

#### The components of this product are reported in the following inventories:

CA. DSL : not determined

AICS : not determined

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
H360D : May damage the unborn child.  
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.

### Full text of other abbreviations

Repr. : Reproductive toxicity  
Resp. Sens. : Respiratory sensitisation  
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonised System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organisation; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardisation; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organisation for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Re-



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pembrolizumab / Berahyaluronidase alfa Subcutaneous Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 14.04.2025
4.1	15.10.2025	7725086-00020	Date of first issue: 06.01.2021

striction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Repr. 1B	H360D
STOT RE 1	H372

### Classification procedure:

Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN